6 assets in Solitary Osseous Plasmacytoma

Therapeutic assets addressing Solitary Osseous Plasmacytoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Dexasone Solitary Osseous Plasmacytoma	Memorial Sloan Kettering Cancer Center	P2	B (57)
Azacitidine Solitary Osseous Plasmacytoma	Memorial Sloan Kettering Cancer Center	P2	CCC (53)
Lenalidomide Solitary Osseous Plasmacytoma	Memorial Sloan Kettering Cancer Center	P2	CCC (53)